{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:58:42Z","timestamp":1781287122731,"version":"3.54.1"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delayed gastric emptying and gastroesophageal reflux represent critical yet frequently underrecognized complications in hospitalized patients, particularly in the context of polypharmacy. While multiple medication classes have been implicated in disrupting gastrointestinal motility, the comprehensive risk spectrum of individual drugs remains poorly characterized. This study aimed to conduct a comprehensive disproportionality analysis to identify drugs associated with delayed gastric emptying and reflux using large-scale pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed adverse event reports from the FDA Adverse Event Reporting System (FAERS; 2004\u20132025; n\u2009&gt;\u200958 million) and validated findings against the Canada Vigilance Adverse Reaction Online Database (CVARD). Disproportionality analysis was performed using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN). Weibull time-to-onset analysis was conducted to characterize temporal patterns of adverse event onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the top 50 drugs screened, 20 demonstrated positive signals across all three algorithms. Glucagon-like peptide-1 (GLP-1) receptor agonists exhibited the strongest associations with gastric motility disorders, with semaglutide showing the highest ROR for impaired gastric emptying (ROR: 80.27; 95% CI: 76.39\u201384.34), validated in CVARD (ROR: 54.17). Insulin formulations, particularly insulin degludec (ROR: 18.90), bisphosphonates, angiotensin receptor blockers, and trofinetide also demonstrated significant signals. Weibull analysis revealed divergent temporal patterns, ranging from early-onset (trofinetide: median 6.6 days) to late-onset (immunoglobulin G: median 535.1 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies a broad spectrum of drug-associated gastric motility disorders with distinct temporal profiles. These findings provide evidence-based priorities for enhanced pharmacovigilance and inform clinical decision-making to mitigate this preventable cause of morbidity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0351731","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:34:56Z","timestamp":1781285696000},"page":"e0351731","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-1949","authenticated-orcid":true,"given":"Zhiheng","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"2","key":"pone.0351731.ref001","first-page":"179","article-title":"Gastrointestinal dysmotility in the ICU","volume":"31","author":"AV Pachisia","year":"2025","journal-title":"Curr Opin Crit Care"},{"key":"pone.0351731.ref002","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clnesp.2022.04.014","article-title":"A systematic review of the definitions and prevalence of feeding intolerance in critically ill adults","volume":"49","author":"B Jenkins","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"13","key":"pone.0351731.ref003","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.3390\/ijms23136917","article-title":"The Role of Inflammatory Mediators in the Development of Gastrointestinal Motility Disorders","volume":"23","author":"T Docsa","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0351731.ref004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11894-024-00954-4","article-title":"The gut in critical illness","volume":"27","author":"JJ Patel","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"pone.0351731.ref005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13054-020-02889-4","article-title":"Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine","volume":"24","author":"A Reintam Blaser","year":"2020","journal-title":"Crit Care"},{"issue":"3","key":"pone.0351731.ref006","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/bjs\/znab436","article-title":"Impact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis","volume":"109","author":"C Kuemmerli","year":"2022","journal-title":"Br J Surg"},{"issue":"6","key":"pone.0351731.ref007","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrab111","article-title":"Impact of routine nasogastric decompression versus no nasogastric decompression after pancreaticoduodenectomy on perioperative outcomes: meta-analysis","volume":"5","author":"K Ammar","year":"2021","journal-title":"BJS Open"},{"issue":"5","key":"pone.0351731.ref008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/MCG.0000000000001772","article-title":"Gastrointestinal dysmotility in critically Ill patients: bridging the gap between evidence and common misconceptions","volume":"57","author":"S Salamone","year":"2023","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"pone.0351731.ref009","first-page":"696","article-title":"Gastrointestinal motility disorders in critically ill patients","volume":"147","author":"D Grajecki","year":"2022","journal-title":"Dtsch Med Wochenschr"},{"key":"pone.0351731.ref010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nutos.2022.06.008","article-title":"Detection of gastroesophageal reflux by multichannel intraluminal impedance technology during mechanical ventilation: the first case series","volume":"44","author":"YP Bar-Lavie","year":"2022","journal-title":"Clinical Nutrition Open Science"},{"issue":"2","key":"pone.0351731.ref011","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jhm.1996","article-title":"Mortality, morbidity, and disease severity of patients with aspiration pneumonia","volume":"8","author":"MJ Lanspa","year":"2013","journal-title":"J Hosp Med"},{"issue":"1","key":"pone.0351731.ref012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12876-025-03837-8","article-title":"Risk factors for enteral feeding intolerance in critically ill patients: an updated systematic review and meta-analysis","volume":"25","author":"S Wang","year":"2025","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"pone.0351731.ref013","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"BS Smith","year":"2012","journal-title":"Chest"},{"issue":"2","key":"pone.0351731.ref014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MCG.0000000000000972","article-title":"Emergency department burden of gastroparesis in the United States, 2006 to 2013","volume":"53","author":"W Hirsch","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"pone.0351731.ref015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clnesp.2024.06.009","article-title":"The effect of mechanical ventilation compared to high-flow nasal cannula on gastric residual volume and reflux events using novel automated technology","volume":"63","author":"M Hellerman Itzhaki","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"pone.0351731.ref016","doi-asserted-by":"crossref","first-page":"1610512","DOI":"10.3389\/fphar.2025.1610512","article-title":"GLP-1R in diabetes mellitus: from basic discovery to therapeutics development","volume":"16","author":"S Li","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0351731.ref017","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"RJ Jalleh","year":"2024","journal-title":"Endocrinology"},{"issue":"10","key":"pone.0351731.ref018","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"RJ Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"pone.0351731.ref019","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"J Ard","year":"2021","journal-title":"Adv Ther"},{"issue":"3","key":"pone.0351731.ref020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"AM Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"issue":"11","key":"pone.0351731.ref021","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"JPH Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0351731.ref022","doi-asserted-by":"crossref","first-page":"1398059","DOI":"10.3389\/fnut.2024.1398059","article-title":"Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity","volume":"11","author":"R Tamayo-Trujillo","year":"2024","journal-title":"Front Nutr"},{"issue":"2","key":"pone.0351731.ref023","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2337\/db13-1764","article-title":"Give the receptor a brake: slowing gastric emptying by GLP-1","volume":"63","author":"J Tong","year":"2014","journal-title":"Diabetes"},{"issue":"3","key":"pone.0351731.ref024","doi-asserted-by":"crossref","first-page":"102994","DOI":"10.1016\/j.dsx.2024.102994","article-title":"Pathogenesis and management of diabetic gastroparesis: An updated clinically oriented review","volume":"18","author":"S Uppaluri","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"pone.0351731.ref025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/ijcp.12821","article-title":"Clinical use of the co-formulation of insulin degludec and insulin aspart","volume":"70","author":"A Kumar","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"3","key":"pone.0351731.ref026","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.1361","article-title":"A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action","volume":"34","author":"SR Drab","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"14","key":"pone.0351731.ref027","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"PC de Groen","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0351731.ref028","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"B Cryer","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"pone.0351731.ref029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.gastro.2006.11.010","article-title":"Actions by angiotensin II on esophageal contractility in humans","volume":"132","author":"A Casselbrant","year":"2007","journal-title":"Gastroenterology"},{"key":"pone.0351731.ref030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/B978-0-323-99618-1.00001-5","article-title":"The renin\u2013angiotensin system in gastrointestinal functions.","volume-title":"Angiotensin","author":"MG Zizzo","year":"2023"},{"issue":"2","key":"pone.0351731.ref031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","article-title":"Charting and sidestepping the pitfalls of disproportionality analysis","volume":"49","author":"M Fusaroli","year":"2026","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0351731.ref032","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"JL Neul","year":"2023","journal-title":"Nat Med"},{"key":"pone.0351731.ref033","doi-asserted-by":"crossref","first-page":"889088","DOI":"10.3389\/fphar.2022.889088","article-title":"Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data","volume":"13","author":"O Sauzet","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"pone.0351731.ref034","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"O Sauzet","year":"2013","journal-title":"Drug Saf"},{"issue":"9","key":"pone.0351731.ref035","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s00431-024-05668-3","article-title":"Nutritional and gastrointestinal manifestations in Rett syndrome: long-term follow-up","volume":"183","author":"TD Berger","year":"2024","journal-title":"Eur J Pediatr"},{"key":"pone.0351731.ref036","first-page":"53","article-title":"Clinical impact of liraglutide as a treatment of obesity","volume":"13","author":"H Alruwaili","year":"2021","journal-title":"Clin Pharmacol"},{"issue":"1","key":"pone.0351731.ref037","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00464-024-11263-2","article-title":"Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"39","author":"TL Kindel","year":"2025","journal-title":"Surg Endosc"},{"issue":"10","key":"pone.0351731.ref038","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"RJ Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"pone.0351731.ref039","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/jada.2003.50026","article-title":"Eating difficulties in girls with Rett syndrome compared with other developmental disabilities","volume":"103","author":"JS Isaacs","year":"2003","journal-title":"J Am Diet Assoc"},{"issue":"3","key":"pone.0351731.ref040","first-page":"153","article-title":"Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research","volume":"61","author":"M Mu\u00f1oz Torres","year":"2014","journal-title":"Endocrinol Nutr"},{"key":"pone.0351731.ref041","first-page":"231","article-title":"Spontaneous reporting systems","author":"J Petracek","year":"2024","journal-title":"Principles and practice of pharmacovigilance and drug safety. Springer International Publishing"},{"key":"pone.0351731.ref042","doi-asserted-by":"crossref","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"PM Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"issue":"3","key":"pone.0351731.ref043","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"R Neha","year":"2021","journal-title":"Hosp Pharm"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:35:06Z","timestamp":1781285706000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351731"}},"subtitle":[],"editor":[{"given":"Timotius Ivan","family":"Hariyanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351731","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}